{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:44:41Z","timestamp":1793857481361,"version":"4.6.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The discovery of novel biomarkers and therapeutic targets is essential for advancing multiple sclerosis (MS) treatment strategies. Lipocalin-2 (LCN2), a 25-kDa glycoprotein, has gained considerable attention for its diverse roles in immune regulation and neuroinflammation. Its expression varies across MS subtypes and disease stages, influencing both peripheral immune responses and central nervous system pathology. Growing evidence has demonstrated the involvement of LCN2 in modulating immune cell function, glial reactivity, and blood-brain barrier integrity. Clinical studies have consistently correlated LCN2 levels in patient biofluids with disease parameters, supporting its potential as a biomarker. Moreover, experimental studies targeting LCN2 have shown promising therapeutic potential. This review examines the role of LCN2 in MS, focusing on its impact on peripheral immune cells, neuroinflammation, and its viability as a biomarker and therapeutic target. We also discuss the relevance of LCN2-targeting therapies within the evolving MS treatment landscape, underscoring the need for further research in this area.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1718318","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T05:41:27Z","timestamp":1772602887000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting lipocalin-2 for multiple sclerosis: a dual role in diagnosis and therapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Ruqayya","family":"Afridi","sequence":"first","affiliation":[{"name":"Department of Pharmacology, School of Medicine, Kyungpook National University","place":["Daegu, Republic of Korea"]},{"name":"Department of Biomedical Sciences, Brain Korea 21 Four Kyungpook National University (KNU) Convergence Educational Program of Biomedical Sciences for Creative Future Talents, Kyungpook National University","place":["Daegu, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Ha","family":"Lee","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Kyungpook National University","place":["Daegu, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minsoo","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, New Drug Discovery Center (NDDC), Daegu Gyeongbuk Medical Innovation Foundation (K-MEDI hub)","place":["Daegu, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoungho","family":"Suk","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Medicine, Kyungpook National University","place":["Daegu, Republic of Korea"]},{"name":"Department of Biomedical Sciences, Brain Korea 21 Four Kyungpook National University (KNU) Convergence Educational Program of Biomedical Sciences for Creative Future Talents, Kyungpook National University","place":["Daegu, Republic of Korea"]},{"name":"Brain Science and Engineering Institute, Kyungpook National University","place":["Daegu, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"a028936","DOI":"10.1101\/cshperspect.a028936","article-title":"Multiple sclerosis pathology","volume":"8","author":"Lassmann","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.737211","article-title":"Systematic review of the socioeconomic consequences in patients with multiple sclerosis with different levels of disability and cognitive function","volume":"12","author":"Kavaliunas","year":"2021","journal-title":"Front Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2016.08.001","article-title":"Lipocalin-2 as a therapeutic target for brain injury: an astrocentric perspective","volume":"144","author":"Suk","year":"2016","journal-title":"Prog Neurobiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.5273-08.2009","article-title":"Lipocalin-2 is an autocrine mediator of reactive astrocytosis","volume":"29","author":"Lee","year":"2009","journal-title":"J Neurosci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.542282","article-title":"Lipocalin-2 protein deficiency ameliorates experimental autoimmune encephalomyelitis: the pathogenic role of lipocalin-2 in the central nervous system and peripheral lymphoid tissues","volume":"289","author":"Nam","year":"2014","journal-title":"J Biol Chem"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1015372","article-title":"Fecal lcn-2 level is a sensitive biological indicator for gut dysbiosis and intestinal inflammation in multiple sclerosis","volume":"13","author":"Yadav","year":"2022","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiad157","article-title":"Lipocalin-2 as a mediator of neuroimmune communication","volume":"116","author":"Afridi","year":"2024","journal-title":"J Leukoc Biol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-nutr-071816-064559","article-title":"Lipocalin 2: an emerging player in iron homeostasis and inflammation","volume":"37","author":"Xiao","year":"2017","journal-title":"Annu Rev Nutr"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3109\/1354750X.2015.1123354","article-title":"The potential of lipocalin-2\/ngal as biomarker for inflammatory and metabolic diseases","volume":"20","author":"Abella","year":"2015","journal-title":"Biomarkers"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2014.12.006","article-title":"Diverse functional roles of lipocalin-2 in the central nervous system","volume":"49","author":"Jha","year":"2015","journal-title":"Neurosci Biobehav Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.5607\/en.2014.23.2.155","article-title":"Lipocalin-2 acts as a neuroinflammatogen in lipopolysaccharide-injected mice","volume":"23","author":"Jin","year":"2014","journal-title":"Exp Neurobiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2023.137497","article-title":"Astrocyte lipocalin-2 modestly effects disease severity in a mouse model of multiple sclerosis while reducing mature oligodendrocyte protein and mrna expression","volume":"815","author":"Kalinin","year":"2023","journal-title":"Neurosci Lett"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1212\/NXI.0000000000000191","article-title":"Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination","volume":"3","author":"Al Nimer","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2015.06.005","article-title":"From the periphery to the brain: lipocalin-2, a friend or foe","volume":"131","author":"Ferreira","year":"2015","journal-title":"Prog Neurobiol"},{"key":"B15","unstructured":"das Neves\n              SP\n            \n          \n          Braga\n          Universidade do Minho (Portugal\n          Studying the role of lipocalin-2 in the pathophysiology of multiple sclerosis-looking beyond the brain\n          \n          2015"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2023.101783","article-title":"Lipocalin-2 promotes adipose-macrophage interactions to shape peripheral and central inflammatory responses in experimental autoimmune encephalomyelitis","volume":"76","author":"Sciarretta","year":"2023","journal-title":"Mol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.931388","article-title":"Sustained infiltration of neutrophils into the cns results in increased demyelination in a viral-induced model of multiple sclerosis","volume":"13","author":"Skinner","year":"2022","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbab025","article-title":"Dichotomous roles of neutrophils in modulating pathogenic and repair processes of inflammatory bowel diseases","volume":"4","author":"Chen","year":"2021","journal-title":"Precis Clin Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"uxae115","DOI":"10.1093\/cei\/uxae115","article-title":"Proteomic analysis reveals dysregulation of peripheral blood neutrophils in patients with multiple sclerosis","volume":"219","author":"Smith","year":"2025","journal-title":"Clin Exp Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1615\/critrevimmunol.2015012127","article-title":"Lipocalin-2 in the inflammatory activation of brain astrocytes","volume":"35","author":"Lee","year":"2015","journal-title":"Crit Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2022.577872","article-title":"Lipocalin-2 does not influence eae clinical score but it increases inflammation in central nervous system","volume":"368","author":"das Neves","year":"2022","journal-title":"J Neuroimmunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2023.156235","article-title":"Tnf-alpha\/stat1\/cxcl10 mutual inflammatory axis that contributes to the pathogenesis of experimental models of multiple sclerosis: A promising signaling pathway for targeted therapies","volume":"168","author":"Rahmat-Zaie","year":"2023","journal-title":"Cytokine"},{"key":"B23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00418-022-02096-y","article-title":"Astroglial and oligodendroglial markers in the cuprizone animal model for de- and remyelination","volume":"158","author":"Castillo-Rodriguez","year":"2022","journal-title":"Histochem Cell Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s12264-022-00906-w","article-title":"Lipocalin-2-mediated insufficient oligodendrocyte progenitor cell remyelination for white matter injury after subarachnoid hemorrhage via scl22a17 receptor\/early growth response protein 1 signaling","volume":"38","author":"Li","year":"2022","journal-title":"Neurosci Bull"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/glia.24245","article-title":"Lipocalin 2 attenuates oligodendrocyte loss and immune cell infiltration in mouse models for multiple sclerosis","volume":"70","author":"Gasterich","year":"2022","journal-title":"Glia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/glia.22342","article-title":"Lipocalin 2 is a novel immune mediator of experimental autoimmune encephalomyelitis pathogenesis and is modulated in multiple sclerosis","volume":"60","author":"Berard","year":"2012","journal-title":"Glia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1096\/fj.12-222257","article-title":"Secreted protein lipocalin-2 promotes microglial M1 polarization","volume":"27","author":"Jang","year":"2013","journal-title":"FASEB J"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2012.00033","article-title":"Lipocalin 2 is present in the eae brain and is modulated by natalizumab","volume":"6","author":"Marques","year":"2012","journal-title":"Front Cell Neurosci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515624560","article-title":"Cerebrospinal fluid lipocalin 2 in patients with clinically isolated syndromes and early multiple sclerosis","volume":"22","author":"Khalil","year":"2016","journal-title":"Mult Scler"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2022.577810","article-title":"Serum levels of lipocalin-2 are elevated at early times in african american relapsing remitting multiple sclerosis patients","volume":"364","author":"Kalinin","year":"2022","journal-title":"J Neuroimmunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e32685","article-title":"Mir-24-3p and mir-484 are potential biomarkers for neurodegeneration in multiple sclerosis","volume":"10","author":"Al-Temaimi","year":"2024","journal-title":"Heliyon"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2017.11.004","article-title":"Remyelination modulators in multiple sclerosis patients","volume":"103","author":"Al-Temaimi","year":"2017","journal-title":"Exp Mol Pathol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s12026-022-09352-2","article-title":"Lipocalin 2-not only a biomarker: A study of current literature and systematic findings of ongoing clinical trials","volume":"71","author":"Asaf","year":"2023","journal-title":"Immunol Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2024.12.029","article-title":"A review on multiple sclerosis: unravelling the complexities of pathogenesis, progression, mechanisms and therapeutic innovations","volume":"567","author":"Rida Zainab","year":"2025","journal-title":"Neuroscience"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1446944","article-title":"Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients","volume":"19","author":"Rommer","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012186.pub2","article-title":"Adverse effects of immunotherapies for multiple sclerosis: A network meta-analysis","volume":"11","author":"Tramacere","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1101\/2025.01.24.25321100","article-title":"Comparison of B-cell depletion versus natalizumab for treatment of multiple sclerosis: A semi-supervised causal analysis","author":"DiSanto","year":"2025","journal-title":"medRxiv"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e1010809","DOI":"10.1371\/journal.ppat.1010809","article-title":"Lipocalin-2 is an essential component of the innate immune response to acinetobacter baumannii infection","volume":"18","author":"Sheldon","year":"2022","journal-title":"PloS Pathog"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200892","article-title":"Lipocalin 2 deficiency dysregulates iron homeostasis and exacerbates endotoxin-induced sepsis","volume":"189","author":"Srinivasan","year":"2012","journal-title":"J Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1718318\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T05:41:28Z","timestamp":1772602888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1718318\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2026.1718318"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1718318","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"article-number":"1718318"}}